WO2019088709A3 - Information providing method for predicting ovarian cancer prognosis by using nc886 gene - Google Patents

Information providing method for predicting ovarian cancer prognosis by using nc886 gene Download PDF

Info

Publication number
WO2019088709A3
WO2019088709A3 PCT/KR2018/013126 KR2018013126W WO2019088709A3 WO 2019088709 A3 WO2019088709 A3 WO 2019088709A3 KR 2018013126 W KR2018013126 W KR 2018013126W WO 2019088709 A3 WO2019088709 A3 WO 2019088709A3
Authority
WO
WIPO (PCT)
Prior art keywords
ovarian cancer
information providing
providing method
gene expression
expression level
Prior art date
Application number
PCT/KR2018/013126
Other languages
French (fr)
Korean (ko)
Other versions
WO2019088709A2 (en
Inventor
이용선
안지혜
이연수
최정혜
Original Assignee
국립암센터
경희대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 국립암센터, 경희대학교 산학협력단 filed Critical 국립암센터
Publication of WO2019088709A2 publication Critical patent/WO2019088709A2/en
Publication of WO2019088709A3 publication Critical patent/WO2019088709A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Abstract

The present invention relates to a composition which is capable of diagnosing, preventing or treating ovarian cancer on the basis of an nc886 gene expression level. The present invention also relates to an information providing method for predicting the prognosis of ovarian cancer patients by confirming an ovarian cancer subtype and an nc886 gene expression level in ovarian cancer patients. Herein, the information providing method includes an information providing method for identifying the nc886 gene expression level with expression patterns of other genes related to nc886. The present invention also relates to a use of a composition for predicting an ovarian cancer prognosis, the composition comprising an agent for measuring the nc886 gene expression level. Therefore, the present invention can exhibit an effect of preventing or treating ovarian cancer by inhibiting nc886 gene expression and can diagnose ovarian cancer or predict the prognosis of ovarian cancer patients by measuring the nc886 gene expression level. In addition, the present invention analyzes the nc886 expression level to predict ovarian cancer metastasis or resistance to an anticancer agent and thus is effective as an information providing method for predicting an ovarian cancer prognosis.
PCT/KR2018/013126 2017-10-31 2018-10-31 Information providing method for predicting ovarian cancer prognosis by using nc886 gene WO2019088709A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2017-0144330 2017-10-31
KR20170144330 2017-10-31

Publications (2)

Publication Number Publication Date
WO2019088709A2 WO2019088709A2 (en) 2019-05-09
WO2019088709A3 true WO2019088709A3 (en) 2019-06-27

Family

ID=66333411

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/013126 WO2019088709A2 (en) 2017-10-31 2018-10-31 Information providing method for predicting ovarian cancer prognosis by using nc886 gene

Country Status (2)

Country Link
KR (1) KR102082462B1 (en)
WO (1) WO2019088709A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024063562A1 (en) * 2022-09-22 2024-03-28 차의과학대학교 산학협력단 Analytic method for diagnosing ovarian cancer resistant to paclitaxel

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011095623A2 (en) * 2010-02-05 2011-08-11 Febit Holding Gmbh miRNA IN THE DIAGNOSIS OF OVARIAN CANCER
WO2012054824A2 (en) * 2010-10-22 2012-04-26 Vermillion, Inc. Prognostic biomarkers in patients with ovarian cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011095623A2 (en) * 2010-02-05 2011-08-11 Febit Holding Gmbh miRNA IN THE DIAGNOSIS OF OVARIAN CANCER
WO2012054824A2 (en) * 2010-10-22 2012-04-26 Vermillion, Inc. Prognostic biomarkers in patients with ovarian cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AHN, JI-HYE: "nc886 is induced by TGF-beta and suppresses the microRNA pathway in ovarian cancer", NATURE COMMUNICATIONS, vol. 9, 21 March 2018 (2018-03-21), pages 1 - 14, XP055620928 *
LEE, KWANBOK: "Precursor miR-886, a novel noncoding RNA repressed in cancer, associates with PKR and modulates its activity", RNA, vol. 17, no. 6, 2011, pages 1076 - 1089, XP055620936 *
LI, JING-HUA: "E2Fl-directed activation of nc886 mediates drug resistance in cervical cancer cells via regulation of major vault protein", INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, vol. 10, no. 9, 15 September 2017 (2017-09-15), pages 9233 - 9242, XP055620941 *
PARK, JONG-LYUL: "Epigenetic regulation of noncoding RNA transcription by mammalian RNA polymerase III", EPIGENOMICS, vol. 9, no. 2, 18 January 2017 (2017-01-18), pages 171 - 187, XP055620932 *

Also Published As

Publication number Publication date
KR102082462B1 (en) 2020-02-27
KR20190049609A (en) 2019-05-09
WO2019088709A2 (en) 2019-05-09

Similar Documents

Publication Publication Date Title
BRPI0919882A8 (en) METHODS TO EVALUATE RNA PATTERNS
EP4242329A3 (en) Use of markers including filamin a in the diagnosis and treatment of prostate cancer
WO2014144657A3 (en) Compositions and methods for cancer prognosis
EP2558598A4 (en) Biomarkers based on a multi-cancer invasion-associated mechanism
WO2015094995A3 (en) Gene signature biomarkers of tumor response to pd-1 antagonists
MX350533B (en) Pancreatic cancer biomarkers and uses thereof.
EP3744859A3 (en) Microrna biomarker for the diagnosis of gastric cancer
BR112018015698A2 (en) ? diagnostic and prognostic methods for cardiovascular disease and events?
MX355020B (en) Lung cancer biomarkers and uses thereof.
WO2014140896A3 (en) Method for the diagnosis, prognosis and treatment of cancer metastasis
WO2015094996A3 (en) Pd-l1 gene signature biomarkers of tumor response to pd-1 antagonists
WO2015073896A3 (en) Biomarkers for psma targeted therapy for prostate cancer
WO2015095862A3 (en) Microrna biomarkers for ovarian cancer
BR112015009438A2 (en) use of a ly75 binding antibody, method of detecting, diagnosing and / or evaluating or monitoring cancer progression and method for identifying an agent for the treatment or prophylaxis of a cancer
WO2013057581A3 (en) Composite biomarkers for non-invasive screening, diagnosis and prognosis of colorectal cancer
DE602009001116D1 (en) Method for the detection of an oral squamous cell carcinoma and means for its suppression
CA2839777C (en) Methods for the prognostic and/or diagnostic of neurodegenerative disease, methods to identify candidate compounds and compounds for treating neurodegenerative disease
EA201790549A1 (en) PREDICTIVE AND PROGNOSTIC BIOMARKERS ASSOCIATED WITH ANTIANGIOGENIC TREATMENT OF MALIGNANT TUMOR
WO2013062261A3 (en) Newly identified colon cancer marker and diagnostic kit using the same
NZ701527A (en) Diagnostic gene marker panel for colorectal cancer
WO2008073629A3 (en) Bifunctional predictors of cancer treatment sensitivity and resistance
MX2007010001A (en) Pharmacogenomic markers for prognosis of solid tumors.
WO2017042625A3 (en) Molecular subtyping, prognosis and treatment of prostate cancer
MX2021012347A (en) Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasm.
BR112016029562A2 (en) methods to treat, diagnose and predict hematologic malignancy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18872614

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18872614

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 18872614

Country of ref document: EP

Kind code of ref document: A2